Hostname: page-component-586b7cd67f-l7hp2 Total loading time: 0 Render date: 2024-11-28T03:04:02.201Z Has data issue: false hasContentIssue false

Levetirazetam psychosis

Published online by Cambridge University Press:  13 August 2021

C. Vilella Martín*
Affiliation:
Psychiatry, Complejo Asistencial Universitario de León, León, Spain
M.Á. Alonso De La Torre López
Affiliation:
Psychiatry, Complejo Asistencial Universitario de León, León, Spain
P. García Vázquez
Affiliation:
Psychiatry, Complejo Asistencial Universitario de León, León, Spain
I. Gonzalez Rodríguez
Affiliation:
Psychiatry, Complejo Asistencial Universitario de León, León, Spain
S. Nuñez Sevillano
Affiliation:
Psychiatry, Complejo Asistencial Universitario de León, León, Spain
A. Serrano García
Affiliation:
Psychiatry, Complejo Asistencial Universitario de León, León, Spain
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Levetirazetam is an antiepileptic drug with psychiatric adverse reactions. It includes psychosis, paranoia or hallucinations. The frequency is less than 1%.

Objectives

To describe and study a case of Psychosis produced by Levetirazetam

Methods

Retrospective review of clinical records and complementary test, including psychiatry, electrophysiology and neurology. Diagnosis schales such as Salamanca Questionnaire were used as suport.

Results

A 42-year-old woman diagnosed with tuberous sclerosis and undergoing treatment with levetirazetam acudes to the emergency department for behavioral disorders. She has presented an episode of aggression against a relative threatening him with a kitchen knife. The family reports that since the change in antiepilepticus 1 month ago, the patient has presented strange behaviors. Te Patient is conscious, uncooperative. Barely Approachable. Suspicious of her surroundings, with psychomotor restlessness, self-reference ideas and sparse speech. Auditory hallucinations seem to be present, as well as depressed and irritable mood. Psychic and somatic anxiety is found. Levetirazetam is discontinued, being replaced by valproic acid. Risperidone is started at a 3 mg dose. Treatment is well tolerated, and clinical stability is achived. Cluster A personality traits are found. Complementary test Blood and Urine simples, Imaging tests (CT and MRI), electroencephalogram and Electrocardiogram show no alterations

Conclusions

Levetirazetam can cause psychiatric adverse effects. it is important to make a proper diagnosis before a first psychotic outbreak in later life. Drugs that can produce psychiatric side effects should be identified and patients should be inform.

Disclosure

No significant relationships.

Type
Abstract
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2021. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.